Clinical trial
A Phase 1b/2a Dose Escalation Study to Assess the Safety and Feasibility of Transendocardial Delivery of 3 Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
NCT00555828 is registered in ClinicalTrials.gov with Angioblast Systems as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a Dose Escalation Study to Assess the Safety and Feasibility of Transendocardial Delivery of 3 Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
- Lead sponsor
- Angioblast Systems
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- March 31, 2008
- Completion date
- December 31, 2013
- Enrollment
- 25 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.